Revenue from sales of vascular products grew 17% (18.8%) to $123.4 million.
Revenue from sales of neuro products grew 6.7% (10.5%) to $90.3 million.
The gross margin was almost stagnant at 63%.
The company reported an adjusted operating income of $7.8 million, down from $8.8 million posted a year ago.
The company reported an adjusted EPS of $0.01, down from $0.12 a year ago.
The company's Lightning Flash product launch is expected in Q1 2023, six weeks later than the previous mid-Q4 2022 estimate, and an incremental headwind of $4-6 million from foreign currency translations.
Guidance: Penumbra expects 2022 total revenue of $840-$845 million, up 12-13% Y/Y (15-16% in constant currency), down from previous guidance of $860-$875 million and the consensus of $860.97 million.
Looking forward to 2023, the company expects to achieve a $1 billion total revenue.
Price Action: PEN shares closed 3.5% lower at $151.88 on Thursday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.